Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27410574 | 1.00 | KMT2A (0.64) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL5550978 | 0.90 | KMT2A (0.76) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL14008332 | 0.87 | KMT2A (0.64) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL18510206 | 0.86 | KMT2A (0.61) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL7113140 | 0.86 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL13525077 | 0.86 | KMT2A (0.73) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL3140809 | 0.86 | KMT2A (0.73) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29423575 | 0.85 | KMT2A (0.81) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL178687 | 0.85 | KMT2A (0.81) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29397906 | 0.85 | KMT2A (0.81) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| EP-4313051-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | Virginia Commonwealth University (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022212471-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | KMT2A 3025/4885EPHX2 578/4885FABP7 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.